Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 9.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,365,245 shares of the company’s stock after acquiring an additional 278,466 shares during the quarter. JPMorgan Chase & Co.’s holdings in Dyne Therapeutics were worth $42,570,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Chung Wu Investment Group LLC purchased a new position in Dyne Therapeutics in the 3rd quarter valued at about $30,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 25.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after buying an additional 1,109 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Dyne Therapeutics by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after buying an additional 955 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Dyne Therapeutics by 275.1% in the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock valued at $100,000 after buying an additional 7,697 shares during the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Dyne Therapeutics during the second quarter valued at approximately $111,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Stifel Nicolaus lifted their target price on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. HC Wainwright lowered their price objective on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Evercore decreased their price target on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, December 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, December 8th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $35.14.

Insider Buying and Selling

In other news, Director Brian S. Posner purchased 3,000 shares of the company’s stock in a transaction on Friday, March 6th. The stock was bought at an average cost of $15.06 per share, for a total transaction of $45,180.00. Following the completion of the purchase, the director directly owned 11,500 shares of the company’s stock, valued at $173,190. The trade was a 35.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 14.14% of the stock is owned by corporate insiders.

Dyne Therapeutics Stock Down 1.3%

Shares of DYN opened at $17.56 on Friday. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $25.00. The company’s fifty day moving average is $16.96 and its two-hundred day moving average is $17.45. The firm has a market cap of $2.90 billion, a PE ratio of -4.96 and a beta of 1.34. The company has a quick ratio of 22.25, a current ratio of 22.25 and a debt-to-equity ratio of 0.15.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.